Efficacy of a Cellular Allogeneic Bone Graft in Foot and Ankle Arthrodesis Procedures

A cellular allogeneic bone graft can be used in patients at high risk for nonunion after arthrodesis surgery. This study explores the utility and efficacy of MAP3 in foot and ankle arthrodesis procedures. Map3 is a cellular allogeneic bone graft that contains osteogenic, osteoconductive, osteoinductive, and angiogenic properties. A total of 23 mostly high-risk patients were included in this study. The overall fusion rate was 83%. Univariate analysis demonstrated diabetic patients remain at risk of recurrent nonunion (P<.001) despite supplementation with MAP3. These data demonstrate successful fusion in high-risk patients when MAP3 is used.